Product
CIC Vaccine
1 clinical trial
2 indications
Indication
COVID-19Indication
InfluenzaClinical trial
A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Healthy Participants ≥ 50 to ≤ 80 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2023-07-25